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Summary 
 
Background: Diversity in metronidazole susceptibility and genotypes of Helicobacter 
pylori have been reported with varying results in different areas.  
Aims: To investigate the prevalence of multiple strain infection in a symptomatic Chinese 
population and to determine the metronidazole susceptibility pattern and genotypic 
characteristics of these infecting strains. 
Methods: Gastric biopsies from antrum, body and cardia were taken during upper 
endoscopy in symptomatic patients referred to our Department. Pooled cultures and 
single colony isolates were obtained and tested for metronidazole susceptibility and 
RAPD fingerprint patterns.  
Results: Four hundred and sixty-one isolates were successfully cultured from 46 patients. 
Fifty-seven percent of subjects had metronidazole resistant strains. Among them, 77% 
carried a mixture of sensitive and resistant strains, non-uniformly distributed in the 
gastric mucosa. Mixed genotypes were found by RAPD typing in 24% of subjects.  These 
did not correlate with the metronidazole susceptibility / resistance pattern.   
Conclusion: H. pylori infections with mixed metronidazole sensitive/resistant strains and 
mixed genotypes are common in Hong Kong. This makes it prudent to use bacterial 
strains from several biopsy sites when testing for traits such as drug resistance or 
virulence in relation to disease.  
Introduction 
 
Helicobacter pylori establishes long-term chronic infections in the human gastric 
mucosa that can lead to active chronic gastritis and peptic ulcer disease [1,2], and is an 
early risk factor for gastric adenocarcinoma and mucosa-associated lymphoid tissue 
lymphoma [3, 4].  Metronidazole (Mtz) is frequently included as one component in 
multidrug treatment regimens. However, the prevalence of Mtz resistance (MtzR) in 
some populations is very high, and this decreases the overall success rate of Mtz-based 
eradication regimens [5,6, 7]. 
 
Two related chromosomal nitroreductase genes, rdxA (HP0954) and frxA 
(HP0642) in the genome sequence, have been implicated in susceptibility and resistance 
to Mtz of H. pylori strains from diverse parts of the world, including East Asia [8, 9, 10, 
11]. The nitroreductase enzymes these genes encode can activate Mtz by converting it 
from a harmless prodrug to a mutagenic and bactericidal agent (probably hydroxylamine). 
Most MtzR clinical isolates contain loss of function mutations in rdxA, and inactivation 
of rdxA in MtzS strains is generally sufficient to make them resistant to moderate levels 
of Mtz (16 micrograms/ml, up from 1.5 micrograms per ml, when measured as in the 
present experiments).  Resistance to higher levels of Mtz is common in clinical isolates 
(typically some half of those that are MtzR), and can be achieved by inactivation of frxA 
(an rdxA homolog, located elsewhere in the chromosome). In our hands, this depends on 
the strain already being mutant in rdxA [9]. Another group has suggested that frxA 
inactivation by itself might be  sufficient to render a MtzS strain MtzR [10]. Studies 
demonstrating that Mtz activation is mutagenic [12] had suggested that yet other cellular 
nitroreductases might also activate Mtz when present in high concentration, but the full 
hierarchy of nitroreductases that can contribute to Mtz toxicity to H. pylori has not been 
elucidated. 
 
 H. pylori is an extremely diverse species, and independent clinical isolates can 
usually be distinguished by any of several DNA fingerprinting methods, including the  
random amplified polymorphic DNA (RAPD) method used here [13]. Differences in 
DNA patterns of isolates from a particular patient indicate presence of more than one 
strain. However, studies of the frequency of mixed infections has given seemingly 
conflicting results, with some indicating that most infected persons harbor only one  H. 
pylori strain [13,14,15], and others indicating frequent mixed infection by more than one 
strain [16,17,18].  
       Antimicrobial susceptibility testing has usually been applied to pools of colonies 
from a primary culture of gastric antrum alone. It has been noted however, that H. pylori 
isolates with identical RAPD patterns may show different patterns of Mtz susceptibility 
[17,19,20], although studies of the MtzR fractions from mixed but predominantly MtzS 
infections can sometimes identify strains of other genotype. Other anecdotal evidence has 
suggested that different strains can sometimes predominate in different sites. Most 
analyses of H. pylori in infected individuals have been carried out using US or European 
residents, but there is emerging evidence that different H. pylori genotypes predominate 
in different human populations [21], and that the spectrum of gastroduodenal diseases 
that H. pylori causes also differs regionally [22]. Therefore, the aims of this study were to 
investigate the prevalence of multiple strain infection in a symptomatic Chinese 
population and to determine the metronidazole susceptibility pattern and genotype 
variation of these infecting strains. 
 
Materials and Methods 
Subjects and Specimens 
 From November 1998 to June 1999, subjects presenting with upper abdominal 
symptoms referred for upper endoscopy to the Endoscopy Unit, Department of Medicine, 
Queen Mary Hospital and who fulfilled the inclusion and exclusion criteria were enrolled 
prospectively into the study. Subjects giving informed consent were included if they were 
between age 18 to 85 years old, and with no previous history of H. pylori eradication and 
no evidence of active bleeding on endoscopic examination. They were excluded if they 
have taken antibiotics, proton pump inhibitors, bismuth-containing compounds, or H2-
receptor antagonists within the recent four weeks; had a history of gastrectomy, or had 
severe concomitant medical illness.  
Forty six H. pylori positive subjects were included in this study. There were 27 
males and 19 females, with a mean age of 56 years, ranging from 22 to 85 years. All 
patients were ethnic Chinese residents of Hong Kong. No data on prior metronidazole 
exposure of these specific patients was available. However, typically such patients may 
have had about two to three courses of metronidazole therapy (for other ailments) during 
the preceding ten to twenty years. 
 Three gastric biopsies were taken for bacterial culture, one each from the antrum, 
body and cardia of the stomach of each patient. Each biopsy was taken from similar sites 
of antrum (2cm from the pylorus), body (greater curvature, midway between pylorus and 
oesophageo-gastric junction) and cardia (greater curvature, 4cm from the OG junction) of 
the stomach. Further biopsies were taken for rapid urease test and histology examination, 
after the biopsies for culture have been taken. All endoscopies were performed by a 
single endoscopist (BCYW) to ensure accurate collection of specimens from different 
sites of the stomach. Each biopsy specimen for culture was placed in a tube containing 
0.5 ml of brain heart infusion (BHI, Oxoid, Basingstoke, UK) medium with 20% glycerol 
and immediately frozen at –700C until further use.  
 
Single and Multiple colony Strains Isolation  
       Each biopsy specimen was cultured on selective media (Columbia agar with 7% 
horse blood and H. pylori supplement; Oxoid, Basingstoke, UK) under microaerophilic 
atmosphere produced by a gas-generation system (CampyGenTM; Oxoid, Basingstoke 
UK) at 37 0C for 3 to 6 days. H. pylori was identified by Gram stain morphology and 
biochemical testing. Two to four single colonies from each primary culture were picked 
randomly and sub-cultured to obtain single colony isolates, and the rest of the colonies on 
the same plate were then pooled to obtain multiple colony isolates. All single colonies 
had a low passage level (less than three passages) prior to susceptibility testing. A total of 
two to eleven single colony isolates and one to three multiple colony isolates were 
obtained from each patient. 
 
Determination of Mtz Susceptibility and Selection of Mtz Resistant Isolates 
       All H. pylori cultures derived from single, and also from multiple colonies (pools 
of over five colonies) were tested for susceptibility to Mtz. Briefly, H. pylori cultures 
were suspended in BHI broth and adjusted to a McFarland turbidity of 1 (3x108 cfu/ml). 
Ten μl aliquots of each suspension were then spread and plated on medium containing 8 
μg/ml Mtz and on control medium that was free of Mtz. Growth on Mtz containing 
medium indicated resistance. Resistant colonies from pools were re-plated again on the 
same medium and re-grown to obtain pure MtzR cultures. 
 
Preparation of Genomic DNA 
       For each patient and each biopsy site, H. pylori genomic DNA was prepared from 
unselected single colony isolates, and also from pools of more than ten colonies and from 
Mtz- selected isolates if available. Bacteria were grown to confluency, harvested with 
sterile cotton swab applicators, and washed once by centrifugation with TE buffer (10mM 
Tris-HCl, 1mM EDTA, pH 8.0). Genomic DNA was prepared using the QIAamp Tissue 
Kit (Qiagen GmbH, Germany). The DNA concentration was determined spectro-
photometrically at 260 nm. 
 
RAPD Fingerprinting 
       RAPD (or arbitrarily primed PCR) DNA fingerprinting was used to detect DNA 
sequence diversity among H. pylori isolates[7]. Two arbitrary primers used in this study 
were 1281 (5’-AACGCGCAAC) and 1254 (5’-CCGCAGCCAA), and were synthesized 
by Genosys Biotechnologies (London, UK). PCR was carried out in a volume of 25 μl, 
containing 10 ng of H. pylori genomic DNA; 4 mM MgCl2; 20 pmol of primer; 1 U of 
Taq DNA polymerase (Boehringer Mannheim GmbH, Germany);  250 mM each of 
dCTP, dGTP, dATP, dTTP in 10 mM Tris-HCl (pH 8.3); 50 mM KCl; and 0.001% 
gelatin. PCR was performed with a thermal cycler (PTC-200, MJ Research, USA), with 
an initial step of denaturing target DNA at 94 0C for 5 min. This was followed by 40 
cycles each of 940 C for 1 min, 360 C for 1 min , 720 C for 2 min, and then a final cycle of 
720 C for 10 min. The PCR products were analyzed using 2% agarose gel electrophoresis. 
A positive (known sample of H. pylori DNA) and a negative control were included in 
each set of PCRs. When different RAPD profiles were obtained from isolates of a 
particular patient, the RAPD fingerprinting was repeated again, using fresh DNA 
preparations, to ensure that the differences were real.   
 
Results 
Endoscopic diagnosis showed gastritis in 16 patients (35%), duodenal ulcer in 15 
patients (33%), gastric ulcer in 12 patients (26%), and gastric cancer in three patients 
(7%). All cancers were proven histologically.  
 
Bacterial culture 
       H. pylori was successfully cultured from all three gastric sites (antrum, body and 
cardia) in 32 of 46 patients, from two of the three sites in ten subjects, and from one of 
the three sites in four subjects. All these 120 sets of cultures (41 from antrum, 42 from 
body, 37 from cardia) were also represented by two to five related single colony isolates 
per biopsy site, giving a total of 418 isolates. All isolates were tested for susceptibility to 
Mtz. 
 
Metronidazole resistance 
Subjects were classified into three groups based on metronidazole susceptibility 
patterns from both pools and single colony isolates. The first group, called the MtzS 
group, consisted of twenty out of 46 patients (43.5%) from whom only Mtz-susceptible 
(MtzS) H. pylori was cultured. The second group, called the MtzR group, consisted of six 
patients (13%) from whom all single colony isolates and pools were MtzR. The third 
group, called the mixed group, consisted of 20 patients from whom both MtzS and MtzR 
H. pylori were cultured. A simplified description of findings is given in Table 1. It was 
striking that with four of the 46 patients (Nos. 9, 39, 78 and 84) in the mixed group 
(8.7%) the pools seemed to be purely MtzS, but one or more of the single colony isolates 
were clearly MtzR. Around one third of the H. pylori infections in non-ulcer dyspepsia, 
duodenal ulcer and gastric cancer patients were MtzS, but two third of the infections in 
gastric ulcer patients were MtzS (Table 2). Due to the small sample size, there was no 
statistical significant difference in the Mtz susceptibility and disease status. 
The prevalence of MtzR correlated directly with the number of sites of biopsies 
obtained and the number of colonies (both pooled and single isolates) tested. When only 
the pooled cultures from either the antrum or the body were analyzed, the observed 
prevalence of MtzR were 32% and 36% respectively (Table 3). This increased to 46% 
when pooled cultures from both antrum and body were included, and further to 59% 
when all sites and single colony isolates were included. There was no obvious preference 
for colonization of the antrum vs. body and cardia with the MtzS or MtzR strains. 
  
H. pylori was eradicated by triple or quadruple therapy containing metronidazole 
from each of the twelve (100%) patients that our tests had indicated were probably 
infected only with MtzS H. pylori. Conversely, of the 17 patients with MtzR strains who 
had metronidazole-based therapy, 12 (71%) of them had successful eradication and 5 of 
them did not. There was a significantly higher eradication rate in patients with MtzS H. 
pylori than those with MtzR strains (p<0.001). However, there was no significant 
difference in the eradication rate of MtzR strains by using regimes with or without  
metronidazole, but the numbers in each subgroup were small.   
 
RAPD Fingerprinting of H. pylori 
      The genetic diversity of H. pylori strains in a given patient was assessed by RAPD 
fingerprinting using 298 single colony isolates obtained from different gastric sites, 120 
pooled cultures and 43 MtzR isolates, when present. Two different primers were used in 
separate reactions to give better sensitivity.  
Uniform RAPD fingerprint patterns were found in comparisons of single colony 
isolates, pooled cultures and the MtzR fraction of a MtzR/MtzS mixed infection (when 
present) in 35 of 46 (76%) patients (14 of 20 (70%) patients with MtzR/MtzS mixed 
infection) (Figure 1). Different RAPD fingerprinting patterns (overall genotype) were 
always found in different patients, as expected. More important, in 11 of the 46 (23.9%) 
patients, at least one isolate differed completely in RAPD profile from the other isolates 
from the same patient, and thus probably constituted different strains. Among them, nine 
patients had two different strains (Figure 2) and the other two patients had three different 
strains. In two patients (patients 8, 12) the different strains were detected among different 
single colony isolates. In four patients (patients 11, 28, 47, 52) the different strains were 
detected by using Mtz-selected as well as unselected isolates (Figure 3).  In another four 
patients (patients 8, 12, 78, 91) the different strains were detected by using two instead of 
just one arbitrary primer (Figure 4). Results of RAPD patterns by using two ng of DNA 
were the same as using 10 ng DNA (Figure 5).  
More than one RAPD pattern was observed in 31%, 27%, 17% of non-ulcer 
dyspepsia, duodenal ulcer and gastric ulcer patients, respectively. The isolates from the 
three gastric cancer patients were uniform in RAPD pattern in each case. Had we only 
compared the RAPD fingerprint patterns from pools from different biopsy sites (antrum, 
body and cardia) using a single RAPD primer, then the detected prevalence of mixed 
infections would have been reduced to 6.5% (3/46). 
 
Correlation between Metronidazole susceptibility pattern and RAPD fingerprinting 
  More than one RAPD fingerprint pattern was found in three  (patient 2, 8 and 85) 
of 20 (15%) patients with pure MtzS strains; one (patient 47) of six (17%) patients with 
pure MtzR strains and seven (patient 11, 12, 28, 52, 78, 86, 91) of 20 (35%) patients with 
mixed MtzS/R strains (overall p=0.33)(Table 1). On the other hand, mixed MtzS/R 
strains were found in 13 out of 35 (37%) patients with a single RAPD fingerprint pattern 
and seven out of 11 (64%) patients with more than one RAPD pattern (p=0.17). There 
were trends that patients with mixed MtzS/R strains were more likely to have more than 
one RAPD pattern, and vice versa, although these did not reach statistical significance. 
 
Discussion 
 
We studied the susceptibility of H. pylori to metronidazole from infected adults in 
Hong Kong, in relation to overall bacterial genotype. This entailed phenotypic tests and 
arbitrarily primed PCR (RAPD) fingerprinting, carried out using both single colony 
isolates and pools of bacteria recovered from each of several biopsy sites per patient.  
More than half of our cohort of infected patients (26 of 46) carried at least some MtzR H. 
pylori. It was striking however that in most of these cases (at least 20 out of 26), the 
infections were mixed, containing both MtzS and MtzR organisms. The MtzS and MtzR 
isolates were often (13/20, 65%) of the same RAPD type. That is, they were closely 
matched in overall genotype. This is in accord with the suggestion that MtzR clinical 
isolates often arise during infections initiated by MtzS organisms by de novo Mtz-
induced as well as selected mutation [8, 19]. It may also be explained by recent findings 
that Mtz is mutagenic for H. pylori, and indications that MtzR strains may be less 
vigorous than MtzS strains [10,12, J. Y. Jeong, and D. E. Berg, unpublished results].  
 
 Our definition of MtzR is the ability to grow in the presence of eight micrograms 
per ml of Mtz. This was chosen for the present large scale tests based on long established 
criteria [9], and indications from our own recent studies that most (but not all) clinical 
isolates resistant to 8 μg/ml (using testing protocol presented here) are resistant to 16 
μg/ml, and that about half of them are resistant to 32 μg/ml [9]. We found that resistance 
to only 8 μg/ml is attributable to leaky mutations in rdxA. Resistance to 16 μg/ml but not 
32 μg/ml reflects null mutations in rdxA, and resistance to 32 μg/ml reflects null 
mutations in rdxA and frxA [9 and, J. Y. Jeong, and D. E. Berg, unpublished results]. 
Megraud et al had suggested that only resistance to at least 32 μg/ml predicted failure of 
Mtz-based eradication therapy [23]. The observation that 71% of patients in our study 
who were infected with MtzR strains had successful eradication of the infection may 
suggest that the threshold for metronidazole resistance in our study might be set too low. 
The high prevalence of MtzR and MtzS/R mixed infection has been important 
clinically: all patients that seemed to be infected only by MtzS strains were successfully 
treated. The 30% treatment failures occurred only in patients that had been colonized with 
at least some MtzR H. pylori. In this context, it was also remarkable that some MtzR 
infections were nevertheless eradicated by Mtz-based therapy [present results, 24,25]. 
This might reflect sometimes achieving higher effective concentrations of Mtz in the 
gastric mucosa than even "resistant" strains can tolerate.  
There was a discrepancy in results of some MtzR tests using single colonies and 
pools: four patients judged from tests using pools to have purely MtzS infections yielded 
at least one single colony isolate with a bona fide MtzR phenotype. Similarly discrepant 
results have also been reported by others [26]. Some of these cases might reflect chance, 
stemming from our having tested different colonies individually and in pools, and the 
relatively few colonies available for pooling from some of our biopsies. Perhaps also 
affecting this might be the apparently lower "fitness" of many MtzR H. pylori strains, 
suggested by inspection of colony size [10], and findings that MtzR H. pylori tend to be 
lost from mixed cultures when grown in direct competition with MtzS strains [J. Y. Jeong 
and D. E. Berg, unpublished results]. 
Several earlier studies have reported that individuals can be infected by strains of 
more than one genotype, with the fraction of persons found to carry multiple strains 
ranging from 0 to 85% (mean 20%) [14,15,17,18,19,27-33].  Some of the strains we 
recovered from mixed infections (24% of infections analyzed) were in a small minority, 
and were found only because numerous single colonies or Mtz-selected colonies were 
analyzed. The differences in apparent prevalence of such mixed infections in different 
reports can be attributed to a combination of factors, including sampling strategy used: 
from one vs. several gastric sites, and the sites of biopsy (all antrum, vs. antrum, body 
and cardia); tests of pools vs. single colonies from each biopsy; analysis of drug resistant 
fractions as well as unselected strains, to increase chance of detecting minority 
subpopulations; and the sensitivity of the strain typing method used. In any case, it is now 
clear that tests of Mtz susceptibility using only H. pylori from antral sites, as had been 
quite typical of studies in the past, may often not fully sample the entire H. pylori 
population throughout the stomach. We suggest that several different sites need to be 
analyzed, at least including both the antrum and the corpus. 
We might expect the actual chance of finding mixed infections to also reflect the 
overall risk of infection in the society under study. However, a clinical trial in Guangzhou, 
China (where the overall risk of H. pylori infection should be more than in Hong Kong), 
had indicated that new adult infections are uncommon [34]. If this finding is applicable to 
the present Hong Kong Chinese population, it is attractive to imagine that the mixed 
infections by different genotypes found here may represent a long-term stable association, 
one that has persisted for years. Whether this indicates specialization of certain strains for 
just a subset of gastric mucosal niches remains to be determined. 
In conclusion, our study has shown that mixed MtzS/R infections are common in 
Hong Kong, and that genotypes are not uniformly distributed throughout the gastric 
mucosa. This makes it prudent to study strains from several biopsy sites when testing for 
traits such as drug resistance or virulence in relation to disease. Infections that were 
mixed in terms of overall genotype were found in 24% of patients, and this did not 
correlate with the 43.5 % of infections that were mixed with regard to Mtz susceptibility. 
Further studies are needed to address issues such as the effects of MtzR on virulence, the 
importance of Mtz-induced mutation in bacterial adaptation and evolution during chronic 
infection, competition among strains during mixed infection vs. the possibility of 
specialization of certain H. pylori strains for particular gastric sites. 
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Table 1.  Metronidazole susceptibility and RAPD patterns of H. pylori isolates from 24 
out of 46 patients 
 
 
                                                          Mtz Susceptibility Pattern   RAPD Pattern 
   
   Patient   Diagnosis Multiple Colony                Single Colony  Isolates   Pattern   No.   Pattern 
 
    Mtz-sensitive (total = 20)* 
         2          NUD As, Bs, Cs  AS1s,AS2s,AS3s,BS1s,BS2s,BS3s, uniform    2 mixed 
          CS1s,CS2s    
         8          NUD As, Bs, Cs  AS1s,AS2s,BS1s,BS2s,CS1s,CS2s  uniform    2 mixed 
        85         GU As, Bs, Cs  AS1s,AS2s,AS3s,BS1s,BS2s,CS1s,  uniform        2 mixed 
                                                                 CS2s,CS3s    
 
     Mtz-resistant (total = 6)* 
         47        DU Ar  AS1r,AS2r    uniform    2(Ar) mixed 
 
 
     Mixed (total = 20)  
         9          GU As, Bs, Cs  AS1s,AS2r,BS1s,BS2s,CS1s,CS2s,CS3s mixed    1 single 
        11         DU Ar, Bs  AS1r,AS2s,BS1s,BS2s  mixed    2(Ar) mixed 
        12         NUD Ar, Bs  AS1s,AS2s,AS3r,AS4s,BS1s,BS2r,CS1r, 
                                                                 CS2r,CS3r     mixed    2 mixed 
        19         NUD As, Br, Cs  AS1s,AS2s,AS3r,BS1s,BS2s,CS1s,CS2s mixed    1 single 
        20         NUD As, Br, Cr   AS1s,AS2sAS3s,AS4s,AS5s,BS1r,BS2r,        
                                                                  BS3r,CS1r,CS2r    mixed    1 single 
        28         NUD As, Br, Cr  AS1s,AS2r,BS1s,BS2s,CS1s,CS2r  mixed    3(Br,Cr) mixed 
        38         NUD As, Br, Cr  AS1r,AS2r,BS1s,BS2s,CS1r,CS2s,CS3s mixed    1 single 
        39         DU As, Bs, Cs  AS1s,AS2s,BS1r,BS2s,CS1r,CS2s mixed    1 single 
        51         GU Ar, Bs, Cs  AS1s,AS2s,BS1s,BS2s,BS3s,CS1s,CS2s mixed    1 single 
        52         DU Ar, Bs, Cs  AS1s,AS2s,BS1r,BS2s,CS1s,CS2s mixed    2(Ar) mixed 
        53         NUD As, Br, Cr  AS1s,AS2s,BS1r,BS2r,CS1s,CS2s mixed    1 single 
        56         CA As, Br, Cr  AS1s,AS2s,AS3s,BS1s,BS2s,BS3s, 
     CS1s,CS2s,CS3s   mixed    1 single 
        57         DU Ar, Cs  AS1s,AS2s,CS1s,CS2s     mixed    1 single 
        60         NUD Ar, Br, Cr  AS1s,AS2s,AS3s,BS1s,BS2s,BS3s,CS1s, 
                                                                  CS2s,CS3s         mixed    1 single 
        63         DU As, Bs, Cr  AS1s,AS2s,BS1s,BS2s,BS3s,CS1s,CS2s mixed    1 single 
        78         NUD As, Bs, Cs  AS1s,AS2s,BS1s,BS2s,BS3r,CS1s,CS2s  mixed    2 mixed 
        84         NUD Bs  BS1r,BS2s,BS3s,BS4s                    mixed    1 single 
        86         GU Br, Cr   BS1r,BS2r,BS3r,CS1s,CS2s,CS3s  mixed    2 mixed 
        91         DU Ar, Br, Cr  AS1r,AS2r,BS1s,BS2s,BS3s,CS1r, 
CS2s,CS3r    mixed    3(Ar) mixed 
       105        CA Br,Cr   AS1r,AS2r,AS3s,AS4s,AS5s,BS1r,BS2r, 
                                                                 BS3r,CS1r,CS2s,CS3s  mixed    1 single 
          
 
*For pure Mtz-sensitive and pure Mtz-resistant group, only those with mixed RAPD 
patterns were shown here. In the pure Mtz-sensitive group, 3 out of 20 were shown, 
and for the pure Mtz-resistant group, 1 out of 6 was shown. 
 
Notes: A: Antrum; B: Body; C: Cardia; S: Single colony isolate; s: Mtz sensitive;  r: 
Mtz resistant; Ar,Br,Cr : Mtz-seleceted  isolates;  NUD: non-ulcer dyspepsia;  DU: 
duodenal ulcer;  GU: gastric ulcer. 
Isolates in Bold character: different RAPD pattern compared with others. 
 
 
Table 2.   Metronidazole Susceptibility Patterns in Different Diseases 
 
 
      Diseases        No. of patients MtzS (%) MtzR/Mixed (%)  
 
      Non ulcer dyspepsia            16                 6 (37.5)             10 (62.5)              
      Duodenal ulcer                     15                5 (33.3)             10 (66.7)             
      Gastric ulcer                         12                8 (66.7)               4 (33.3)              
      Gastric cancer                        3                1 (33.3)               2 (66.7)              
      Total                                     46              20 (43.5)             26 (56.5)              
 
Table 3. Results of Metronidazole susceptibility by different biopsy sites 
 
Sites     Available Patients    MtzS (%) MtzR (%) 
 
Antrum     41  28 (68)  13 (32) 
Body      42  27 (64)  15 (36) 
Cardia       37  22 (59)  15 (41) 
Antrum + Body    37  20 (54)  17 (46) 
Antrum + Cardia    35  19 (54)  16 (46) 
Body + Cardia     34  18 (53)  16  (47) 
Antrum + Body + Cardia   32  16 (50)  16 (50) 
Antrum + Body + Cardia + Single isolates   32           13 (41)  19 (59)  
 
 
Figure Legend 
 
Fig 1. RAPD fingerprinting from a representative patient indicating identical RAPD 
patterns using two sets of primers in multiple colony isolates (MCI)(A: antrum; B: body; 
C: cardia), single colony isolates (SCI)(A1, B1, C1from antrum, body, cardia, etc) and 
Mtz-selected colony isolates (MSI)(Ar, Br, Cr from antrum, body and cardia respectively). 
(M: marker) 
 
Fig 2. Two different RAPD fingerprintings were found for strains isolated from body and 
fundus. (MCI: multiple colony isolates; SCI: single colony isolates; MSI: Mtz-selected 
colony isolates, similar to figure 1) 
 
Fig 3. Mtz-selected isolate from the antrum (Ar) demonstrated a different RAPD pattern 
from strains isolated from multiple colony isolates and single colony isolates. (M: marker; 
MCI: multiple colony isolates; SCI: single colony isolates; MSI: Mtz-selected colony 
isolates, similar to figure 1) 
 
Fig 4. Three different RAPD patterns were found by primer 1281, but not by primer 1254. 
(M: marker; MCI: multiple colony isolates; SCI: single colony isolates; MSI: Mtz-
selected colony isolates, similar to figure 1) 
 
Fig 5. Two pairs of single colony isolates from two representative patients (A, B) each 
demonstrated two different RAPD patterns, which were confirmed by using 2 ng and 10 
ng templete concentrations, and by using primers 1281 and 1254.  
 
 
